Ethical hurdles for translational research

Radiation Research

Volumn 160, Issue 1, 2003, Pages 1-4

  Sugarman, Jeremy ^a,c   McKenna, W Gillies ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; ETHICS; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH;

EID: 0038343839     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3030     Document Type: Review

References (30)

1. W. F. Crowley, Jr. and S. O. Their, A program to facilitate clinical research in an AHC: The first five years. Acad. Med. 76, 403-409 (2001).
2. A. Eggermont and H. Newell, Translational research in clinical trials: The only way forward. Eur. J. Cancer 37, 1965-1969 (2001).
3. Translational Research Program Committee, Translational Research Program. Int. J. Radiat. Oncol. Biol. Phys. 51, 75-87 (2001).
4. J. D. Minna and A. F. Gazdar, Translational research comes of age. Nat. Med. 2, 974-975 (1996).
5. A. C. Gelijns, N. Rosenberg and A. J. Moskowitz, Capturing the unexpected benefits of medical research. N. Engl. J. Med. 339, 693-698 (1998).
6. A. K. Rustgi, Translational research: what is it? Gastroenterology 116, 1285 (1999).
7. P. D. Minor, Eradication and cessation programmes. Br. Med. Bull. 62, 213-224 (2002).
8. Office of Inspector General, Institutional Review Boards: A Time for Reform. DHHS, OEI-01-97-00193. U. S. Government Printing Office, Washington, DC, June 1998.
9. Association of American Medical Colleges, Task Force on Financial Conflicts of Interest in Clinical Research, Protecting subjects, preserving trust, promoting progress: policy and guidelines for the oversight of individual financial interests in human subjects research. Association of American Medical Colleges, Washington, DC, December 2001.
10. Association of American Medical Colleges, Task Force on Financial Conflicts of Interest in Clinical Research, Protecting subjects, preserving trust, promoting progress II: Principles and recommendations for oversight of an institution's financial interests in human subjects research. Association of American Medical Colleges, Washington, DC, October 2002.
11. W. E. Powers, J. J. Kinzie, A. J. Demidecki, J. S. Bradfield and A. Feldman, A new system of field shaping for external-beam radiation therapy. Radiology 108, 407-411 (1973).
12. M. Baumann, S. M. Bentzen, W. Doerr, M. C. Joiner, M. Saunders, I. F. Tannock and H. D. Thames, The translational research chain: Is it delivering the goods? Int. J. Radiat. Oncol. Biol. Phys. 49, 345-351 (2001).
13. R. Busse and I. Fleming, A critical look at cardiovascular translational research. Am. J. Physiol. 277, H1655-H1660 (1999).
14. R. L. Strausberg, K. H. Buetow, M. R. Emmert-Buck and R. D. Klausner, Trends Genet. 16, 103-6 (2000).
15. E. J. Hall, The contribution of the physical sciences to the development of radiation therapy. J. Surg. Oncol. 24, 248-57 (1983).
16. J. P. Kahn, A. M. Mastroianni and J. Sugarman, Eds., Beyond Consent: Seeking Justice in Research. Oxford University Press, New York, 1998.
17. N. E. Kass, J. Sugarman, R. Faden and M. Schoch-Spana, Trust: The fragile foundation of contemporary biomedical research. Hastings Center Rep. 26, 25-29 (1996).
18. J. Sugarman, Ethical considerations in leaping from bench to bedside. Science 24, 2071-2072 (1999).
19. T. H. Doyle, F. Mornex and W. G. McKenna, The clinical implications of gemcitabine radiosensitization. Clin. Cancer Res. 7, 226-228 (2001).
20. A. D. Colevas, J. M. Brown, S. Hahn, J. Mitchell, K. Camphausen and C. N. Coleman, Development of investigational radiation modifiers. J. Natl. Cancer Inst. 95, 646-651 (2003).
21. B. J. Druker, C. L. Sawyers, H. Kantarjian, D. J. Resta, S. F. Reese, J. M. Ford, R. Capdeville and M. Talpaz, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
22. B. J. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger, J. M. Ford, N. B. Lydon, H. Kantarjian, R. Capdeville and C. L. Sawyers, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl. J. Med. 344, 1031-1037 (2001).
23. B. A. Chabner, A. L. Boral and P. Multani, Translational research: Walking the bridge between idea and cure-seventeenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 58, 4211-4216 (1988).
24. J. S. G. Montaner, M. V. O'Shaughnessy and M. T. Schechter, Industry-sponsored clinical research: a double-edged sword. Lancet 358, 1893-1895 (2001).
25. D. Nelson and R. Weiss, Penn researchers sued in gene therapy death: Teen's parents also named ethicist as defendant. section A, p. A3, Washington Post, September 19, 2000.
26. L. Smith and J. F. Byers, Gene therapy in the post-Gelsinger era. In JONAS Health Law Ethics and Regulations (D. L. Flarey, Ed.), pp 104-110. Lippincott Williams & Wilkins, Philadelphia, 2002.
27. National Bioethics Advisory Commission, Research involving human biological materials: Ethical issues and policy guidance. National Bioethics Advisory Commission, Rockville, MD, 1999.
28. Moore v Regents of University of California. 51 Cal3d 120, 1990. [Excerpts available at http://www.richmond.edu/-wolf/moore.htm]
29. F. L. Bookstein, Biotech and the watchdog role of universities. p. A15, Washington Post, July 30, 2001.
30. J. S. Pober, C. S. Neuhauser and J. M Pober, Obstacles facing translational research in academic medical centers. FASEB J. 15, 2303-2313 (2001).